China: A New Biopharma Model Emerging
Professor Richard Barker, founder of New Medicine Partners reflects on China’s very different approach to the biopharma industry. Napoleon once said: “China is a sleeping giant. Let her sleep, for…
Address: No.97,Lane 1518,Guangfulin Road,Songjiang District,Shanghai,201620,P.R.China
Tel: 86 2161 026 752
Web: http://www.hoborchem.com/
Shanghai Hobor Chemical Co., Ltd is a production-oriented enterprise dedicated to pharmaceutical intermediates and active pharmaceutical ingredients synthesis and process development,Hobor Chemical has been committed to expedite our customer’s R&D and manufacturing in a time and cost effective manner since 2010 the company started.We focuses on developing efficient process technology for intermediates,active ingredients.
Our R&D lab located in Hi-Tech Park of Shanghai,China,the facility located in Fengxin industrial area,Jiangxi Province,employees experienced chemistry and medicine R&D team and equipped with the state of the art instruments.to be able to complete the low temperature of -80 to 300 high temperature a variety of reactions.Our products are strictly controlled by the LC, NMR,MS ensure customer satisfaction with every batch of products. We have established very good relationship with many global customers since company started.
Custom Synthesis As a innovative research company and active high-tech building block supplier, we are eager to become your professional partner in the following fields:
1. Heterocyclic chemistry and it’s synthetic technology
2. APi’s structure and it’s process research3. Cost effective process for pharma intermediates4. Chiral chemicals realted to above region
We provide Explore new synthetic chemistry Synthesis of novel and/or know compounds Substantial experience in process development, scale up and commercialization Able to follow an entire project, from laboratory to pilot production
QA manager is always involved in working together with our marketing colleage to identify suitable supplier, ensure the quality of products, and control the risks in supply chain.
Professor Richard Barker, founder of New Medicine Partners reflects on China’s very different approach to the biopharma industry. Napoleon once said: “China is a sleeping giant. Let her sleep, for…
Chinese ecommerce behemoths Alibaba and JD.com are being used to buy and sell tens of thousands of prescription medicines, skirting regulations in what is a legal grey area. According to…
Andy A. Liu, CEO of CW Data Technologies, a joint venture between WuXi AppTec and China Electronics Data Corporation at the intersection of Big Data and healthcare, discusses emerging trends…
Simon Yam, managing director of Geodis Greater China, shares the importance of the Greater China region to Geodis globally, the region’s strong performance and growth, the strategic importance of the…
Gene Shigekawa, managing partner of MAZ World, shares their recent move to the Hong Kong Science and Technology Park (HKSTP) in 2017, the revolutionary ostrich-derived antibody they hope to further…
Louis Sze, CEO of Personal Surgical Modelling, an exciting Hong Kong start-up in the 3D printing medical technology field, shares the company’s achievements over the past few years, his insights…
K P Tsang, president of the Hong Kong Alliance for Rare Diseases (HKARD), shares the challenges faced by patients with rare diseases and their caregivers in Hong Kong, the areas…
Dr. Harley Seyedin, president of AmCham South China, talks up increasing connectivity in the region, competition and collaboration between the Greater Bay Area cities, and their potential for international life…
Rupert Mok, a veteran of the Hong Kong medtech industry, discusses regulatory alignment between Hong Kong and mainland China, opportunities for collaboration, the consumer ‘wearable’ space, and the state of…
This week, China has fast-tracked approval for 48 “much-needed medicines.” Regulators gave special consideration to new treatments for rare diseases as well as drugs that target serious, life-threatening illnesses, like cancer. Authorities…
One of China’s biggest vaccine manufacturers was found to have falsified rabies vaccine records causing nationwide parenting chaos. Executives from China’s second largest pharmaceutical company, ChangSheng biotechnology (Changsheng literally translates…
Dr. Qiu, could you please introduce your company, H-Guard, to our international readers? “It is clear that our efforts and investments over the past five years have paid off. Just…
See our Cookie Privacy Policy Here
